In this episode, Andy Molnar, CEO of the Digital Therapeutics Alliance discusses reimbursement for digital therapeutics and the pharmacists role in digital care delivery.
In this episode, we review the definition of digital therapeutics, FDA risk classifications and pathways to approval and reimbursement for digital therapeutics and clinical services related.
In this episode, Dr. Dan Hussar, Remington award winner provides useful information to help pharmacists stay up to date and navigate new drug approvals.
In this episode, we’ll focus on 2 new clinically relevant drug approvals impacting both community and hospital pharmacists – suzetrigine and aztreonam-avibactam. We’ll discuss efficacy data which led to their approval, potential adverse effects and counseling points for pharmacists to be aware of.
In this episode, Yara Al-Shaer and transitions of care pharmacist Laressa Bethishou discuss strategies for preventing medication errors during transitions of care, with an emphasis on medication reconciliation, and effective collaboration across healthcare teams.